EMERYVILLE, Calif.--(BUSINESS WIRE)--Researchers at NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, www.novabaypharma.com), a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal and viral infections, have published a seminal paper on the design and synthesis of a new class of stable antimicrobial compounds. The company believes that these compounds, trademarked as Aganocides, have the potential to become a new weapon in the fight against such deadly pathogens as methicillin-resistant Staphylococcus aureus (MRSA). NovaBay is currently conducting human clinical trials of its lead Aganocide compound in two indications.
